Henry Schein (HSIC) 10-Q 4 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 28, 2014	Jul. 28, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Document Period End Date	28-Jun-14	'
Amendment Flag	'false	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'
Current Fiscal Year End Date	'--12-27	'
Entity Central Index Key	'0001000228	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Registrant Name	'HENRY SCHEIN INC	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Common Stock, Shares Outstanding	'	84,832,600

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 28, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$89,698	$188,616
Accounts receivable, net of reserves of $81,932 and $78,298	1,188,143	1,055,216
Inventories, net	1,257,235	1,250,403
Deferred income taxes	66,431	63,865
Prepaid expenses and other	310,496	276,565
Total current assets	2,912,003	2,834,665
Property and equipment, net	292,972	275,888
Goodwill	1,832,377	1,635,005
Other intangibles, net	594,358	417,133
Investments and other	360,044	461,945
Total assets	5,991,754	5,624,636
Current liabilities:	'	'
Accounts payable	755,999	824,495
Bank credit lines	83,671	29,508
Current maturities of long-term debt	6,302	5,441
Accrued expenses:	'	'
Payroll and related	208,886	216,629
Taxes	158,363	145,161
Other	330,680	329,429
Total current liabilities	1,543,901	1,550,663
Long-term debt	665,909	450,233
Deferred income taxes	278,456	198,674
Other liabilities	152,029	139,526
Total liabilities	2,640,295	2,339,096
Redeemable noncontrolling interests	497,927	497,539
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $.01 par value, 240,000,000 shares authorized, 85,022,123 outstanding on June 28, 2014 and 85,622,452 outstanding on December 28, 2013	850	856
Additional paid-in capital	265,469	318,225
Retained earnings	2,505,721	2,398,267
Accumulated other comprehensive income	78,703	67,849
Total Henry Schein, Inc. stockholders' equity	2,850,743	2,785,197
Noncontrolling interests	2,789	2,804
Total stockholders' equity	2,853,532	2,788,001
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$5,991,754	$5,624,636

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 28, 2014	Dec. 28, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, reserves	$81,932	$78,298
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	240,000,000	240,000,000
Common stock, shares outstanding (in shares)	85,022,123	85,622,452

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Income Statement [Abstract]	'	'	'	'
Net sales	$2,615,406	$2,391,810	$5,045,565	$4,685,321
Cost of sales	1,886,934	1,721,954	3,620,380	3,368,474
Gross profit	728,472	669,856	1,425,185	1,316,847
Operating expenses:	'	'	'	'
Selling, general and administrative	547,628	493,791	1,087,073	987,153
Operating income	180,844	176,065	338,112	329,694
Other income (expense):	'	'	'	'
Interest income	3,416	3,303	6,871	6,508
Interest expense	-5,670	-4,890	-10,928	-17,617
Other, net	1,032	-34	4,612	-404
Income before taxes and equity in earnings of affiliates	179,622	174,444	338,667	318,181
Income taxes	-55,322	-54,775	-104,945	-100,627
Equity in earnings of affiliates	2,817	1,766	3,523	2,567
Net income	127,117	121,435	237,245	220,121
Less: Net income attributable to noncontrolling interests	-10,881	-13,005	-18,910	-20,213
Net income attributable to Henry Schein, Inc.	$116,236	$108,430	$218,335	$199,908
Earnings per share attributable to Henry Schein, Inc.:	'	'	'	'
Basic (in dollars per share)	$1.37	$1.26	$2.58	$2.31
Diluted (in dollars per share)	$1.35	$1.23	$2.53	$2.27
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	84,620	86,370	84,716	86,483
Diluted (in shares)	85,980	87,968	86,189	88,205

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Statement of Income and Comprehensive Income [Abstract]	'	'	'	'
Net income	$127,117	$121,435	$237,245	$220,121
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation gain (loss)	6,828	-15,261	14,620	-55,702
Unrealized gain (loss) from foreign currency hedging activities	-772	793	-1,720	634
Unrealized investment gain (loss)	27	-74	38	-83
Pension adjustment gain (loss)	249	269	517	1,007
Other comprehensive income (loss), net of tax	6,332	-14,273	13,455	-54,144
Comprehensive income	133,449	107,162	250,700	165,977
Comprehensive income attributable to noncontrolling interests:	'	'	'	'
Net income	-10,881	-13,005	-18,910	-20,213
Foreign currency translation (gain) loss	-491	1,076	-2,601	2,554
Comprehensive income attributable to noncontrolling interests	-11,372	-11,929	-21,511	-17,659
Comprehensive income attributable to Henry Schein, Inc.	$122,077	$95,233	$229,189	$148,318

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interests [Member]
In Thousands, except Share data
Beginning Balance at Dec. 28, 2013	$2,788,001	$856	$318,225	$2,398,267	$67,849	$2,804
Beginning Balance, shares (in shares) at Dec. 28, 2013	85,622,452	85,622,452	'	'	'	'
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	218,607	0	0	218,335	0	272
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	12,006	0	0	0	12,019	-13
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	-1,720	0	0	0	-1,720	0
Unrealized investment gain (loss), net of tax impact	38	0	0	0	38	0
Pension adjustment gain (loss), net of tax impact	517	0	0	0	517	0
Dividends paid	-274	0	0	0	0	-274
Change in fair value of redeemable securities	-37,124	0	-37,124	0	0	0
Other adjustments	-285	0	-285	0	0	0
Repurchase and retirement of common stock - Value	-151,443	-13	-40,549	-110,881	0	0
Repurchase and retirement of common stock - Shares	'	-1,301,267	'	'	'	'
Stock issued upon exercise of stock options, including tax benefit - Value	28,321	4	28,317	0	0	0
Stock issued upon exercise of stock options, including tax benefit - Shares	'	438,172	'	'	'	'
Stock-based compensation expense - Value	19,505	4	19,501	0	0	0
Stock-based compensation expense - Shares	'	447,901	'	'	'	'
Shares withheld for payroll taxes - Value	-22,373	-1	-22,372	0	0	0
Shares withheld for payroll taxes - Shares	'	-185,135	'	'	'	'
Liability for cash settlement stock-based compensation awards	-244	0	-244	0	0	0
Ending Balance at Jun. 28, 2014	$2,853,532	$850	$265,469	$2,505,721	$78,703	$2,789
Ending Balance, shares (in shares) at Jun. 28, 2014	85,022,123	85,022,123	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CHA1

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014
Statement of Stockholders' Equity [Abstract]	'
Net income attributable to redeemable noncontrolling interests	$18,638
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	2,614
Unrealized gain (loss) from foreign currency hedging activities, tax benefit (tax)	301
Unrealized investment gain (loss), tax benefit (tax)	-24
Pension adjustment gain (loss), tax benefit (tax)	-64
Stock issued upon exercise of stock options, tax benefit	$7,044

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Cash flows from operating activities:	'	'
Net income	$237,245	$220,121
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	73,489	64,236
Accelerated amortization of deferred financing costs	0	6,203
Stock-based compensation expense	19,505	16,732
Provision for losses on trade and other accounts receivable	2,415	2,154
Provision for (benefit from) deferred income taxes	6,009	15,550
Equity in earnings of affiliates	-3,523	-2,567
Distributions from equity affiliates	5,340	6,450
Other	15,453	5,367
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	-86,199	-45,155
Inventories	48,550	82,037
Other current assets	-23,251	-12,924
Accounts payable and accrued expenses	-151,050	-121,453
Net cash provided by (used in) operating activities	143,983	236,751
Cash flows from investing activities:	'	'
Purchases of fixed assets	-37,976	-21,934
Payments for equity investments and business acquisitions, net of cash acquired	-222,857	-33,708
Other	-6,497	-5,071
Net cash provided by (used in) investing activities	-267,330	-60,713
Cash flows from financing activities:	'	'
Proceeds from (repayments of) bank borrowings	53,239	-11,640
Proceeds from issuance of debt	314,787	483,781
Debt issuance costs	0	-1,319
Principal payments for long-term debt	-100,866	-538,000
Proceeds from issuance of stock upon exercise of stock options	21,277	19,452
Payments for repurchases of common stock	-151,443	-151,511
Excess tax benefits related to stock-based compensation	4,579	5,328
Distributions to noncontrolling shareholders	-17,689	-13,008
Acquisitions of noncontrolling interests in subsidiaries	-102,552	-5,754
Net cash provided by (used in) financing activities	21,332	-212,671
Effect of exchange rate changes on cash and cash equivalents	3,097	-6,608
Net change in cash and cash equivalents	-98,918	-43,241
Cash and cash equivalents, beginning of period	188,616	122,080
Cash and cash equivalents, end of period	$89,698	$78,839

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Note 1 – Basis of Presentation
	Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.
	Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.
	The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 28, 2013.
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the six months ended June 28, 2014 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 27, 2014.

Segment_Data

Segment Data	6 Months Ended
	Jun. 28, 2014
Segment Reporting [Abstract]	'
Segment Data	'
	Note 2 – Segment Data
	We conduct our business through two reportable segments: health care distribution and technology and value-added services. These segments offer different products and services to the same customer base. The health care distribution reportable segment aggregates our global dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global animal health group serves animal health practices and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental, animal health and medical groups serve practitioners in 27 countries worldwide.
	Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include financial services on a non-recourse basis, e-services and continuing education services for practitioners.
	The following tables present information about our reportable and operating segments:
					Three Months Ended				Six Months Ended
					June 28,		June 29,		June 28,		June 29,
					2014		2013		2014		2013
	Net Sales:
		Health care distribution (1):
			Dental		$	1,368,481	$	1,259,581	$	2,665,409	$	2,450,376
			Animal health			754,549		666,297		1,409,037		1,305,439
			Medical			403,257		387,887		800,671		776,749
				Total health care distribution		2,526,287		2,313,765		4,875,117		4,532,564
		Technology and value-added services (2)				89,119		78,045		170,448		152,757
			Total		$	2,615,406	$	2,391,810	$	5,045,565	$	4,685,321
	-1	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
		generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	-2	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and
		financial and other services, including e-services and continuing education services for practitioners.
					Three Months Ended				Six Months Ended
					June 28,		June 29,		June 28,		June 29,
					2014		2013		2014		2013
	Operating Income:
		Health care distribution			$	153,578	$	154,682	$	287,397	$	289,142
		Technology and value-added services				27,266		21,383		50,715		40,552
			Total		$	180,844	$	176,065	$	338,112	$	329,694

Debt

Debt	6 Months Ended
	Jun. 28, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 3 – Debt
	Bank Credit Lines
	On September 12, 2012, we entered into a new $500 million revolving credit agreement (the “Credit Agreement”) with a $200 million expansion feature, which expires on September 12, 2017. The interest rate is based on USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. The Credit Agreement provides, among other things, that we are required to maintain certain interest coverage and maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. There was $60.0 million outstanding under this revolving credit facility as of June 28, 2014. As of June 28, 2014, there were $10.1 million of letters of credit provided to third parties under the credit facility.
	As of June 28, 2014, we had various other short-term bank credit lines available, of which $23.7 million was outstanding. At June 28, 2014, borrowings under all of our credit lines had a weighted average interest rate of 1.50%. In July 2014, we extended credit lines with various financial institutions for an additional year.
	Term Loan Note
	On January 9, 2014, we entered into a $100 million term loan, of which none was outstanding as of June 28, 2014.  The interest rate on this note is LIBOR plus 75 basis points.  The note matured on July 9, 2014.
	Private Placement Facilities
	On August 10, 2010, we entered into $400 million private placement facilities with two insurance companies. On April 30, 2012, we increased our available credit facilities by $375 million by entering into a new agreement with one insurance company and amending our existing agreements with two insurance companies. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time during a three year issuance period, through April 26, 2015. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.
	The components of our private placement facility borrowings as of June 28, 2014 are presented in the following table:
		Amount of
		Borrowing		Borrowing
	Date of Borrowing	Outstanding		Rate		Due Date
	2-Sep-10	$	100,000	3.79	%	2-Sep-20
	20-Jan-12		50,000	3.45		20-Jan-24
	January 20, 2012 (1)		50,000	3.09		20-Jan-22
	24-Dec-12		50,000	3		24-Dec-24
	2-Jun-14		100,000	3.19		2-Jun-21
		$	350,000
	(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.
	U.S. Trade Accounts Receivable Securitization
	On April 17, 2013, we entered into a facility agreement of up to $300 million with a bank, as agent, based on the securitization of our U.S. trade accounts receivable. The new facility allowed us to replace public debt (approximately $220 million), which had a higher interest rate at Henry Schein Animal Health (“HSAH”) during February 2013 and provided funding for working capital and general corporate purposes. The financing was structured as an asset-backed securitization program with pricing committed for up to three years. The borrowings outstanding under this securitization facility were $274.4 million as of June 28, 2014. At June 28, 2014, the interest rate on borrowings under this facility was based on the average asset-backed commercial paper rate of 19 basis points plus 75 basis points, for a combined rate of 0.94%.
	We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.
	Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheet.
	Other Loans Payable
	Certain of our subsidiaries have various collateralized and uncollateralized long-term loans payable with interest, with borrowings of $39.6 million outstanding at June 28, 2014, in varying installments through 2018 at interest rates ranging from 2.15% to 5.41%.
	Henry Schein Animal Health
	During the first quarter of 2013, we repaid the then outstanding debt related to the HSAH (formerly Butler Schein Animal Health) transaction using our existing Credit Agreement. As part of this transaction, we recorded a one-time interest expense charge of $6.2 million related to the accelerated amortization of deferred financing costs.

Redeemable_Noncontrolling_Inte

Redeemable Noncontrolling Interests	6 Months Ended
	Jun. 28, 2014
Temporary Equity Disclosure [Abstract]	'
Redeemable Noncontrolling Interests	'
	Note 4 – Redeemable Noncontrolling Interests
	Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the Redeemable noncontrolling interests for the six months ended June 28, 2014 and the year ended December 28, 2013 are presented in the following table:
			June 28,		December 28,
			2014		2013
	Balance, beginning of period		$	497,539	$	435,175
	Decrease in redeemable noncontrolling interests due to
		redemptions		-102,552		-9,028
	Increase in redeemable noncontrolling interests due to business
		acquisitions		61,840		11,542
	Net income attributable to redeemable noncontrolling interests			18,638		39,430
	Dividends declared			-17,276		-19,965
	Effect of foreign currency translation gain (loss) attributable to
		redeemable noncontrolling interests		2,614		-654
	Change in fair value of redeemable securities			37,124		41,039
	Balance, end of period		$	497,927	$	497,539
	Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Comprehensive_Income

Comprehensive Income	6 Months Ended
	Jun. 28, 2014
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]	'
Comprehensive Income	'
	Note 5 – Comprehensive Income
	Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) on foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).
	The following table summarizes our Accumulated other comprehensive income, net of applicable taxes as of:
					June 28,			December 28,
					2014			2013
	Attributable to Redeemable noncontrolling interests:
			Foreign currency translation adjustment		$	1,111		$	-1,503
	Attributable to noncontrolling interests:
			Foreign currency translation adjustment		$	-13		$	-
	Attributable to Henry Schein, Inc.:
		Foreign currency translation gain			$	94,307		$	82,288
		Unrealized gain (loss) from foreign currency hedging activities				-438			1,282
		Unrealized investment loss				-477			-515
		Pension adjustment loss				-14,689			-15,206
			Accumulated other comprehensive income		$	78,703		$	67,849
	Total Accumulated other comprehensive income				$	79,801		$	66,346
	The following table summarizes the components of comprehensive income, net of applicable taxes as follows:
			Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
			2014			2013			2014			2013
	Net income		$	127,117		$	121,435		$	237,245		$	220,121
	Foreign currency translation gain (loss)			6,828			-15,261			14,620			-55,702
	Tax effect			-			-			-			-
	Foreign currency translation gain (loss)			6,828			-15,261			14,620			-55,702
	Unrealized gain (loss) from foreign currency hedging
	activities			-869			932			-2,021			856
	Tax effect			97			-139			301			-222
	Unrealized gain (loss) from foreign currency hedging
	activities			-772			793			-1,720			634
	Unrealized investment gain (loss)			44			-123			62			-138
	Tax effect			-17			49			-24			55
	Unrealized investment gain (loss)			27			-74			38			-83
	Pension adjustment gain			235			343			581			1,263
	Tax effect			14			-74			-64			-256
	Pension adjustment gain			249			269			517			1,007
	Comprehensive income		$	133,449		$	107,162		$	250,700		$	165,977
	The following table summarizes our total comprehensive income, net of applicable taxes as follows:
				Three Months Ended						Six Months Ended
				June 28,			June 29,			June 28,			June 29,
				2014			2013			2014			2013
	Comprehensive income attributable to
		Henry Schein, Inc.		$	122,077		$	95,233		$	229,189		$	148,318
	Comprehensive income attributable to
		noncontrolling interests			188			115			259			189
	Comprehensive income attributable to
		Redeemable noncontrolling interests			11,184			11,814			21,252			17,470
	Comprehensive income			$	133,449		$	107,162		$	250,700		$	165,977

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Note 6 – Fair Value Measurements
	ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for measuring fair value in generally accepted accounting principles.
	ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).
	The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
	• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
	• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	• Level 3— Inputs that are unobservable for the asset or liability.
	The following section describes the valuation methodologies that we used to measure different financial instruments at fair value.
	Investments and notes receivable
	There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value.
	Debt
	The fair value of our debt as of June 28, 2014 and December 28, 2013 was estimated at $755.9 million and $485.2 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, prepayment and make-whole provisions, liquidity levels in the private placement market, variability in pricing from multiple lenders and term of debt.
	Derivative contracts
	Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to intercompany loans and certain forecasted inventory purchase commitments with suppliers.
	The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy.
	Redeemable noncontrolling interests
	Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value based on third-party valuations. The primary factor affecting the future value of redeemable noncontrolling interests is expected earnings and, if such earnings are not achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests subject to put options are adjusted to their estimated redemption amounts each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy. The details of the changes in Redeemable noncontrolling interests are presented in Note 4.
	The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 28, 2014 and December 28, 2013:
				28-Jun-14
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	242	$	-	$	242
			Total assets	$	-	$	242	$	-	$	242
	Liabilities:
		Derivative contracts		$	-	$	2,048	$	-	$	2,048
			Total liabilities	$	-	$	2,048	$	-	$	2,048
	Redeemable noncontrolling interests			$	-	$	-	$	497,927	$	497,927
				28-Dec-13
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	1,235	$	-	$	1,235
			Total assets	$	-	$	1,235	$	-	$	1,235
	Liabilities:
		Derivative contracts		$	-	$	1,142	$	-	$	1,142
			Total liabilities	$	-	$	1,142	$	-	$	1,142
	Redeemable noncontrolling interests			$	-	$	-	$	497,539	$	497,539

Business_Acquisitions

Business Acquisitions	6 Months Ended
	Jun. 28, 2014
Business Combinations [Abstract]	'
Business Acquisitions	'
	Note 7 – Business Acquisitions
	The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.
	On April 2, 2014, we completed our previously announced acquisition of an 80% ownership position in Medivet S.A., a privately held distributor of animal health products and services in Poland. Medivet has annual sales of approximately $80 million.
	On May 22, 2014, we announced that our U.S. Animal Health business, Butler Animal Health Supply LLC (“BAHS”), together with our wholly-owned subsidiary, W.A. Butler Company (“WAB”), entered into a definitive agreement to acquire a 60% ownership position in SmartPak Equine, LLC (“SmartPak”), a privately held provider of equine supplements and horse supplies in the United States.  SmartPak had sales of approximately $105 million in 2013.  BAHS and WAB completed this transaction on June 30, 2014.
	We completed certain other acquisitions during the six months ended June 28, 2014. Such acquisitions were immaterial to our financial statements individually and in the aggregate.
	Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the six months ended June 28, 2014 and June 29, 2013, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.

Plan_of_Restructuring

Plan of Restructuring	6 Months Ended
	Jun. 28, 2014
Restructuring and Related Activities [Abstract]	'
Plan of Restructuring	'
	Note 8 – Plan of Restructuring
	During the year ended December 29, 2012, we incurred restructuring costs of $15.2 million ($10.5 million after taxes) consisting of employee severance pay and benefits related to the elimination of approximately 200 positions; facility closing costs, representing primarily lease terminations and property and equipment write-off costs; and outside professional and consulting fees directly related to the restructuring plan. This restructuring program is complete and we do not expect any additional costs from this program.
	The costs associated with this restructuring have been included in a separate line item, “Restructuring costs” within our consolidated statements of income.
	The following table shows the amounts expensed and paid for restructuring costs that were incurred during the six months ended June 28, 2014 and during our 2013 fiscal year and the remaining accrued balance of restructuring costs as of June 28, 2014, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet:
				Facility
		Severance		Closing
		Costs		Costs		Total
	Balance, December 29, 2012	$	1,826	$	1,231	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,599		-747		-2,346
	Balance, December 28, 2013	$	227	$	484	$	711
	Provision		-		-		-
	Payments and other adjustments		-75		-88		-163
	Balance, June 28, 2014	$	152	$	396	$	548
	The following table shows, by reportable segment, the amounts expensed and paid for restructuring costs that were incurred during the six months ended June 28, 2014 and the 2013 fiscal year and the remaining accrued balance of restructuring costs as of June 28, 2014:
				Technology and
		Health Care		Value-Added
		Distribution		Services		Total
	Balance, December 29, 2012	$	3,043	$	14	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-2,332		-14		-2,346
	Balance, December 28, 2013	$	711	$	-	$	711
	Provision		-		-		-
	Payments and other adjustments		-163		-		-163
	Balance, June 28, 2014	$	548	$	-	$	548

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Jun. 28, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 9 – Earnings Per Share
	Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect.
	A reconciliation of shares used in calculating earnings per basic and diluted share follows:
			Three Months Ended		Six Months Ended
			June 28,	June 29,	June 28,	June 29,
			2014	2013	2014	2013
	Basic		84,620	86,370	84,716	86,483
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units	1,360	1,598	1,473	1,722
		Diluted	85,980	87,968	86,189	88,205

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 28, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 10 – Income Taxes
	For the six months ended June 28, 2014, our effective tax rate was 31.0% compared to 31.6% for the prior year period. The difference between our effective tax rates and the federal statutory tax rates for both periods primarily relates to state and foreign income taxes and interest expense.
	The total amount of unrecognized tax benefits as of June 28, 2014 was approximately $61.5 million, of which $47.2 million would affect the effective tax rate if recognized.  It is expected that the amount of unrecognized tax benefits will change in the next 12 months; however, we do not expect the change to have a material impact on our consolidated financial statements.
	The total amounts of interest and penalties, which are classified as a component of the provision for income taxes, were approximately $10.9 million and $0, respectively, for the six months ended June 28, 2014.
	The tax years subject to examination by major tax jurisdictions include the years 2009 and forward by the U.S. Internal Revenue Service, as well as the years 2005 and forward for certain states and certain foreign jurisdictions.

Derivatives_and_Hedging_Activi

Derivatives and Hedging Activities	6 Months Ended
	Jun. 28, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Hedging Activities	'
	Note 11 – Derivatives and Hedging Activities
	We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our investments, maintaining a strong balance sheet and having multiple sources of capital.
	Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC Topic 815 have been omitted.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Note 12 – Stock-Based Compensation
	Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $10.5 million ($7.3 million after-tax) and $19.5 million ($13.5 million after-tax) for the three and six months ended June 28, 2014, respectively, and $11.4 million ($7.8 million after-tax) and $16.7 million ($11.4 million after-tax) for the three and six months ended June 29, 2013, respectively.
	Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.
	Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013 Stock Incentive Plan, as amended, and our 1996 Non-Employee Director Stock Incentive Plan, as amended (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and restricted stock (including restricted stock units). Since March 2009, equity-based awards have been granted solely in the form of restricted stock and restricted stock units, with the exception of providing stock options to employees for certain pre-existing contractual obligations.
	Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. Prior to 2014, we issued restricted stock that vests solely based on the recipient's continued service over time (primarily four-year cliff) and restricted stock that vests based on our achieving specified performance measurements and the recipient's continued service over time (primarily three-year cliff vesting). Since February 2014, we issue restricted stock that vests solely based on the recipient's continued service over time (primarily four-year cliff vesting under our 2013 Stock Incentive Plan and primarily 13-month cliff vesting under our 1996 Non-Employee Director Stock Incentive Plan) and restricted stock that vests based on our achieving specified performance measurements and the recipient's continued service over time (primarily three-year cliff vesting).
	With respect to time-based restricted stock, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a three-year period as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock based on our closing stock price at time of grant.
	The Plans provide for adjustments to the performance-based restricted stock targets for significant events such as acquisitions, divestitures, new business ventures and share repurchases. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.
	Restricted stock units are awards that we grant to certain employees that entitle the recipient to shares of common stock upon vesting. We grant restricted stock units with the same time-based and performance-based vesting that we use for restricted stock. The fair value of restricted stock units is determined on the date of grant, based on our closing stock price.
	Total unrecognized compensation cost related to non-vested awards as of June 28, 2014 was $102.0 million, which is expected to be recognized over a weighted-average period of approximately 2.4 years.
	The following table summarizes stock option activity under the Plans during the six months ended June 28, 2014:
					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
			Exercise		Life in		Intrinsic
		Shares	Price		Years		Value
	Outstanding at beginning of period	1,323	$	51.53
	Granted	-		-
	Exercised	-440		48.66
	Forfeited	-		-
	Outstanding at end of period	883	$	52.96	2.7		$	58,205
	Options exercisable at end of period	883	$	52.96	2.7		$	58,205
	The following tables summarize the activity of our non-vested restricted stock/units for the six months ended June 28, 2014:
		Time-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	926	$	70.7
	Granted	172		118.69
	Vested	-229		57.66
	Forfeited	-19		79.26
	Outstanding at end of period	850	$	83.71		$	118.86
		Performance-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,078	$	59.85
	Granted	265		110.97
	Vested	-259		70.03
	Forfeited	-14		84.25
	Outstanding at end of period	1,070	$	75.06		$	118.86

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	6 Months Ended
	Jun. 28, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	Note 13 – Supplemental Cash Flow Information
	Cash paid for interest and income taxes was:
		Six Months Ended
		June 28,		June 29,
		2014		2013
	Interest	$	9,712	$	11,200
	Income taxes		95,105		65,246
	During the six months ended June 28, 2014 and June 29, 2013, we had a $2.0 million non-cash net unrealized loss and a $0.9 million of non-cash net unrealized gain related to foreign currency hedging activities, respectively.

Segment_Data_Tables

Segment Data (Tables)	6 Months Ended
	Jun. 28, 2014
Segment Reporting [Abstract]	'
Business segment information	'
					Three Months Ended				Six Months Ended
					June 28,		June 29,		June 28,		June 29,
					2014		2013		2014		2013
	Net Sales:
		Health care distribution (1):
			Dental		$	1,368,481	$	1,259,581	$	2,665,409	$	2,450,376
			Animal health			754,549		666,297		1,409,037		1,305,439
			Medical			403,257		387,887		800,671		776,749
				Total health care distribution		2,526,287		2,313,765		4,875,117		4,532,564
		Technology and value-added services (2)				89,119		78,045		170,448		152,757
			Total		$	2,615,406	$	2,391,810	$	5,045,565	$	4,685,321
	-1	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
		generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	-2	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and
		financial and other services, including e-services and continuing education services for practitioners.
					Three Months Ended				Six Months Ended
					June 28,		June 29,		June 28,		June 29,
					2014		2013		2014		2013
	Operating Income:
		Health care distribution			$	153,578	$	154,682	$	287,397	$	289,142
		Technology and value-added services				27,266		21,383		50,715		40,552
			Total		$	180,844	$	176,065	$	338,112	$	329,694

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 28, 2014
Debt Disclosure [Abstract]	'
Private Placement Facilities	'
		Amount of
		Borrowing		Borrowing
	Date of Borrowing	Outstanding		Rate		Due Date
	2-Sep-10	$	100,000	3.79	%	2-Sep-20
	20-Jan-12		50,000	3.45		20-Jan-24
	January 20, 2012 (1)		50,000	3.09		20-Jan-22
	24-Dec-12		50,000	3		24-Dec-24
	2-Jun-14		100,000	3.19		2-Jun-21
		$	350,000
	(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.

Redeemable_Noncontrolling_Inte1

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 28, 2014
Temporary Equity Disclosure [Abstract]	'
Change in fair value of redeemable noncontrolling interests	'
			June 28,		December 28,
			2014		2013
	Balance, beginning of period		$	497,539	$	435,175
	Decrease in redeemable noncontrolling interests due to
		redemptions		-102,552		-9,028
	Increase in redeemable noncontrolling interests due to business
		acquisitions		61,840		11,542
	Net income attributable to redeemable noncontrolling interests			18,638		39,430
	Dividends declared			-17,276		-19,965
	Effect of foreign currency translation gain (loss) attributable to
		redeemable noncontrolling interests		2,614		-654
	Change in fair value of redeemable securities			37,124		41,039
	Balance, end of period		$	497,927	$	497,539

Comprehensive_Income_Tables

Comprehensive Income (Tables)	6 Months Ended
	Jun. 28, 2014
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]	'
Accumulated other comprehensive income, net of applicable taxes	'
					June 28,			December 28,
					2014			2013
	Attributable to Redeemable noncontrolling interests:
			Foreign currency translation adjustment		$	1,111		$	-1,503
	Attributable to noncontrolling interests:
			Foreign currency translation adjustment		$	-13		$	-
	Attributable to Henry Schein, Inc.:
		Foreign currency translation gain			$	94,307		$	82,288
		Unrealized gain (loss) from foreign currency hedging activities				-438			1,282
		Unrealized investment loss				-477			-515
		Pension adjustment loss				-14,689			-15,206
			Accumulated other comprehensive income		$	78,703		$	67,849
	Total Accumulated other comprehensive income				$	79,801		$	66,346
Components of comprehensive income, net of applicable taxes	'
			Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
			2014			2013			2014			2013
	Net income		$	127,117		$	121,435		$	237,245		$	220,121
	Foreign currency translation gain (loss)			6,828			-15,261			14,620			-55,702
	Tax effect			-			-			-			-
	Foreign currency translation gain (loss)			6,828			-15,261			14,620			-55,702
	Unrealized gain (loss) from foreign currency hedging
	activities			-869			932			-2,021			856
	Tax effect			97			-139			301			-222
	Unrealized gain (loss) from foreign currency hedging
	activities			-772			793			-1,720			634
	Unrealized investment gain (loss)			44			-123			62			-138
	Tax effect			-17			49			-24			55
	Unrealized investment gain (loss)			27			-74			38			-83
	Pension adjustment gain			235			343			581			1,263
	Tax effect			14			-74			-64			-256
	Pension adjustment gain			249			269			517			1,007
	Comprehensive income		$	133,449		$	107,162		$	250,700		$	165,977
Total comprehensive income, net of applicable taxes	'
				Three Months Ended						Six Months Ended
				June 28,			June 29,			June 28,			June 29,
				2014			2013			2014			2013
	Comprehensive income attributable to
		Henry Schein, Inc.		$	122,077		$	95,233		$	229,189		$	148,318
	Comprehensive income attributable to
		noncontrolling interests			188			115			259			189
	Comprehensive income attributable to
		Redeemable noncontrolling interests			11,184			11,814			21,252			17,470
	Comprehensive income			$	133,449		$	107,162		$	250,700		$	165,977

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair value - assets and liabilities measured and recognized on a recurring basis	'
				28-Jun-14
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	242	$	-	$	242
			Total assets	$	-	$	242	$	-	$	242
	Liabilities:
		Derivative contracts		$	-	$	2,048	$	-	$	2,048
			Total liabilities	$	-	$	2,048	$	-	$	2,048
	Redeemable noncontrolling interests			$	-	$	-	$	497,927	$	497,927
				28-Dec-13
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	1,235	$	-	$	1,235
			Total assets	$	-	$	1,235	$	-	$	1,235
	Liabilities:
		Derivative contracts		$	-	$	1,142	$	-	$	1,142
			Total liabilities	$	-	$	1,142	$	-	$	1,142
	Redeemable noncontrolling interests			$	-	$	-	$	497,539	$	497,539

Plan_of_Restructuring_Tables

Plan of Restructuring (Tables)	6 Months Ended
	Jun. 28, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of restructuring reserve by type of cost	'
				Facility
		Severance		Closing
		Costs		Costs		Total
	Balance, December 29, 2012	$	1,826	$	1,231	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,599		-747		-2,346
	Balance, December 28, 2013	$	227	$	484	$	711
	Provision		-		-		-
	Payments and other adjustments		-75		-88		-163
	Balance, June 28, 2014	$	152	$	396	$	548
Schedule of restructuring reserve by segment	'
				Technology and
		Health Care		Value-Added
		Distribution		Services		Total
	Balance, December 29, 2012	$	3,043	$	14	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-2,332		-14		-2,346
	Balance, December 28, 2013	$	711	$	-	$	711
	Provision		-		-		-
	Payments and other adjustments		-163		-		-163
	Balance, June 28, 2014	$	548	$	-	$	548

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Jun. 28, 2014
Earnings Per Share [Abstract]	'
Reconciliation of basic and diluted shares used to calculate earnings per share	'
			Three Months Ended		Six Months Ended
			June 28,	June 29,	June 28,	June 29,
			2014	2013	2014	2013
	Basic		84,620	86,370	84,716	86,483
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units	1,360	1,598	1,473	1,722
		Diluted	85,980	87,968	86,189	88,205

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of the stock option activity under the plans	'
					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
			Exercise		Life in		Intrinsic
		Shares	Price		Years		Value
	Outstanding at beginning of period	1,323	$	51.53
	Granted	-		-
	Exercised	-440		48.66
	Forfeited	-		-
	Outstanding at end of period	883	$	52.96	2.7		$	58,205
	Options exercisable at end of period	883	$	52.96	2.7		$	58,205
Status of non-vested restricted shares/units	'
		Time-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	926	$	70.7
	Granted	172		118.69
	Vested	-229		57.66
	Forfeited	-19		79.26
	Outstanding at end of period	850	$	83.71		$	118.86
		Performance-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,078	$	59.85
	Granted	265		110.97
	Vested	-259		70.03
	Forfeited	-14		84.25
	Outstanding at end of period	1,070	$	75.06		$	118.86

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 28, 2014
Supplemental Cash Flow Elements [Abstract]	'
Cash paid for interest and income taxes	'
		Six Months Ended
		June 28,		June 29,
		2014		2013
	Interest	$	9,712	$	11,200
	Income taxes		95,105		65,246

Segment_Data_Details

Segment Data (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
	number		number
Segment Reporting [Abstract]	'	'	'	'
Number of reportable segments	'	'	2	'
Number of countries served globally	27	'	27	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$2,615,406	$2,391,810	$5,045,565	$4,685,321
Operating income	180,844	176,065	338,112	329,694
Health Care Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	2,526,287	2,313,765	4,875,117	4,532,564
Operating income	153,578	154,682	287,397	289,142
Health Care Distribution [Member] | Dental [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	1,368,481	1,259,581	2,665,409	2,450,376
Health Care Distribution [Member] | Animal Health [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	754,549	666,297	1,409,037	1,305,439
Health Care Distribution [Member] | Medical [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	403,257	387,887	800,671	776,749
Technology and Value-Added Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	89,119	78,045	170,448	152,757
Operating income	$27,266	$21,383	$50,715	$40,552

Debt_Bank_Credit_Lines_Details

Debt - Bank Credit Lines (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Line of Credit Facility [Line Items]	'
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)	1.50%
Revolving credit facility [Member]	'
Line of Credit Facility [Line Items]	'
Revolving credit facility borrowing capacity	$500
Additional credit available under expansion feature of revolving credit facility	200
Revolving credit facility expiration date	12-Sep-17
Outstanding letters of credit provided to third parties	10.1
Line of credit facility, amount outstanding	60
Various other short-term bank credit lines [Member]	'
Line of Credit Facility [Line Items]	'
Line of credit facility, amount outstanding	$23.70

Debt_Shortterm_Details

Debt - Short-term (Details) (Notes payable to banks [Member], USD $)	6 Months Ended
	Jun. 28, 2014	Jan. 09, 2014
Short-term Debt [Line Items]	'	'
Debt instrument, maximum borrowing capacity	'	$100,000,000
Debt instrument, carrying amount	$0	'
Debt instrument, maturity date	9-Jul-14	'
Short-term term loan note rate [Member]	'	'
Short-term Debt [Line Items]	'	'
Debt instrument, basis spread on variable rate	0.75%	'

Debt_Longterm_Details

Debt - Long-term (Details) (USD $)

6 Months Ended

6 Months Ended

6 Months Ended

2 Months Ended

3 Months Ended

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Apr. 30, 2012

Aug. 10, 2010

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Apr. 17, 2013

Jun. 28, 2014

Jun. 28, 2014

Feb. 21, 2013

Mar. 30, 2013

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

Private placement facilities [Member]

U.S. trade accounts receivable securitization [Member]

U.S. trade accounts receivable securitization [Member]

U.S. trade accounts receivable securitization [Member]

Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member]

Henry Schein Animal Health debt [Member]

Henry Schein Animal Health debt [Member]

company

company

Minimum [Member]

Maximum [Member]

Maximum Average [Member]

Private placement facilities maturing in September 2020 [Member]

Private placement facilities maturing in January 2024 [Member]

Private placement facilities maturing in January 2022 [Member]

Private placement facilities maturing in December 2024 [Member]

Private placement facilities maturing in June 2021 [Member]

Average Asset Backed Commercial Paper Rate [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, amount repaid

$100,866,000

$538,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$220,000,000

'

Debt instrument, maximum borrowing capacity

'

'

'

'

400,000,000

'

'

'

'

'

'

'

'

'

300,000,000

'

'

'

'

Private placement facility additional borrowing capacity

'

'

'

375,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of insurance companies providing private placement facilities (in number of insurance companies)

'

'

'

1

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of issuances under private placement facilities

'

'

'

'

'

'5 years

'15 years

'12 years

'

'

'

'

'

'

'

'

'

'

'

Issuance period (in years)

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of borrowing

'

'

'

'

'

'

'

'

2-Sep-10

20-Jan-12

20-Jan-12

24-Dec-12

2-Jun-14

'

'

'

'

'

'

Due date

'

'

'

'

'

'

'

'

2-Sep-20

20-Jan-24

20-Jan-22

24-Dec-24

2-Jun-21

'

'

'

'

'

'

Private placement facility annual payment

'

'

'

'

'

'

'

'

'

'

7,100,000

'

'

'

'

'

'

'

'

Private placement facility annual payment commencement date

'

'

'

'

'

'

'

'

'

'

20-Jan-16

'

'

'

'

'

'

'

'

Long-term debt and capital lease obligations including current maturities

'

'

350,000,000

'

'

'

'

'

100,000,000

50,000,000

50,000,000

50,000,000

100,000,000

274,400,000

'

'

39,600,000

'

'

Debt instrument, interest rate, stated percentage (in hundredths)

'

'

'

'

'

'

'

'

3.79%

3.45%

3.09%

3.00%

3.19%

'

'

'

'

'

'

Accelerated amortization of deferred financing costs

$0

$6,203,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,200,000

Pricing commitment period

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

Debt instrument, interest rate at period end

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.94%

'

'

'

Debt instrument interest rate, stated percentage rate range minimum (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.15%

'

'

Debt instrument interest rate, stated percentage rate range maximum (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.41%

'

'

Debt instrument, variable rate basis at period end

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.19%

'

'

'

Debt instrument, basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.75%

'

'

'

Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

0.30%

'

'

'

'

'

Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

0.35%

'

'

'

'

'

Debt instrument borrowing perentage of facility used for calculating commitment fee (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

Redeemable_Noncontrolling_Inte2

Redeemable Noncontrolling Interests (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Dec. 28, 2013
Components of the change in the redeemable noncontrolling interests [Abstract]	'	'
Balance, beginning of period	$497,539	$435,175
Decrease in redeemable noncontrolling interests due to redemptions	-102,552	-9,028
Increase in redeemable noncontrolling interests due to business acquisitions	61,840	11,542
Net income attributable to redeemable noncontrolling interests	18,638	39,430
Dividends declared	-17,276	-19,965
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	2,614	-654
Change in fair value of redeemable securities	37,124	41,039
Balance, end of period	$497,927	$497,539

Comprehensive_Income_Accumulat

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Dec. 28, 2013
Attributable to Redeemable noncontrolling interests:	'	'	'	'	'
Foreign currency translation adjustment	$1,111	'	$1,111	'	($1,503)
Attributable to noncontrolling interests:	'	'	'	'	'
Foreign currency translation adjustment	-13	'	-13	'	0
Attributable to Henry Schein, Inc.:	'	'	'	'	'
Foreign currency translation gain (loss)	94,307	'	94,307	'	82,288
Unrealized gain (loss) from foreign currency hedging activities	-438	'	-438	'	1,282
Unrealized investment gain (loss)	-477	'	-477	'	-515
Pension adjustment gain (loss)	-14,689	'	-14,689	'	-15,206
Accumulated other comprehensive income (loss)	78,703	'	78,703	'	67,849
Total Accumulated other comprehensive income (loss)	79,801	'	79,801	'	66,346
Components of comprehensive income [Abstract]	'	'	'	'	'
Net income	127,117	121,435	237,245	220,121	'
Foreign currency translation gain (loss)	6,828	-15,261	14,620	-55,702	'
Tax effect	0	0	0	0	'
Foreign currency translation gain (loss)	6,828	-15,261	14,620	-55,702	'
Unrealized gain (loss) from foreign currency hedging activities	-869	932	-2,021	856	'
Tax effect	97	-139	301	-222	'
Unrealized gain (loss) from foreign currency hedging activities	-772	793	-1,720	634	'
Unrealized investment gain (loss)	44	-123	62	-138	'
Tax effect	-17	49	-24	55	'
Unrealized investment gain (loss)	27	-74	38	-83	'
Pension adjustment gain (loss)	235	343	581	1,263	'
Tax effect	14	-74	-64	-256	'
Pension adjustment gain (loss)	249	269	517	1,007	'
Comprehensive income	$133,449	$107,162	$250,700	$165,977	'

Comprehensive_Income_Total_Com

Comprehensive Income - Total Comprehensive Income (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Comprehensive Income Net Of Applicable Taxes [Abstract]	'	'	'	'
Comprehensive income attributable to Henry Schein, Inc.	$122,077	$95,233	$229,189	$148,318
Comprehensive income attributable to noncontrolling interests	188	115	259	189
Comprehensive income attributable to Redeemable noncontrolling interests	11,184	11,814	21,252	17,470
Comprehensive income	$133,449	$107,162	$250,700	$165,977

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 28, 2014	Dec. 28, 2013	Dec. 29, 2012
Fair Value Disclosures [Abstract]	'	'	'
Fair value of debt	$755,900,000	$485,200,000	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	497,927,000	497,539,000	435,175,000
Fair value, measurements, recurring [Member] | Level 1 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Derivative contracts - assets	0	0	'
Total assets	0	0	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	0	0	'
Total liabilities	0	0	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	0	0	'
Fair value, measurements, recurring [Member] | Level 2 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Derivative contracts - assets	242,000	1,235,000	'
Total assets	242,000	1,235,000	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	2,048,000	1,142,000	'
Total liabilities	2,048,000	1,142,000	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	0	0	'
Fair value, measurements, recurring [Member] | Level 3 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Derivative contracts - assets	0	0	'
Total assets	0	0	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	0	0	'
Total liabilities	0	0	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	497,927,000	497,539,000	'
Fair value, measurements, recurring [Member] | Estimate of fair value measurement [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Derivative contracts - assets	242,000	1,235,000	'
Total assets	242,000	1,235,000	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	2,048,000	1,142,000	'
Total liabilities	2,048,000	1,142,000	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	$497,927,000	$497,539,000	'

Business_Acquisitions_Details

Business Acquisitions (Details) (USD $)	6 Months Ended		12 Months Ended		12 Months Ended
	Jun. 28, 2014	Jun. 29, 2013	Dec. 31, 2013	Apr. 02, 2014	Dec. 31, 2013	Jun. 30, 2014
			Medivet [Member]	Medivet [Member]	SmartPak Equine, LLC [Member]	SmartPak Equine, LLC [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'
Acquired equity interest (in hundredths)	'	'	'	80.00%	'	60.00%
Business acquisition, aggregate sales in year of acquisition of acquired companies	'	'	$80,000,000	'	$105,000,000	'
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability	$0	$0	'	'	'	'

Plan_of_Restructuring_Details

Plan of Restructuring (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 28, 2014	Dec. 28, 2013	Dec. 29, 2012
			number
Restructuring and Related Activities [Abstract]	'	'	'
Positions eliminated from operations (in positions)	'	'	200
Restructuring costs	$0	$0	$15,200,000
Restructuring costs after-tax	'	'	10,500,000
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, beginning balance	711,000	3,057,000	'
Provision	0	0	15,200,000
Payments and other adjustments	-163,000	-2,346,000	'
Restructuring Reserve, ending balance	548,000	711,000	3,057,000
Health Care Distribution [Member]	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'
Restructuring costs	0	0	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, beginning balance	711,000	3,043,000	'
Provision	0	0	'
Payments and other adjustments	-163,000	-2,332,000	'
Restructuring Reserve, ending balance	548,000	711,000	'
Technology and Value-Added Services [Member]	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'
Restructuring costs	0	0	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, beginning balance	0	14,000	'
Provision	0	0	'
Payments and other adjustments	0	-14,000	'
Restructuring Reserve, ending balance	0	0	'
Severance costs [Member]	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'
Restructuring costs	0	0	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, beginning balance	227,000	1,826,000	'
Provision	0	0	'
Payments and other adjustments	-75,000	-1,599,000	'
Restructuring Reserve, ending balance	152,000	227,000	'
Facility closing costs [Member]	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'
Restructuring costs	0	0	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, beginning balance	484,000	1,231,000	'
Provision	0	0	'
Payments and other adjustments	-88,000	-747,000	'
Restructuring Reserve, ending balance	$396,000	$484,000	'

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	84,620	86,370	84,716	86,483
Effect of dilutive securities:	'	'	'	'
Stock options, restricted stock and restricted stock units (in shares)	1,360	1,598	1,473	1,722
Diluted (in shares)	85,980	87,968	86,189	88,205

Income_Taxes_Details

Income Taxes (Details) (USD $)	6 Months Ended
	Jun. 28, 2014	Jun. 29, 2013
Income Tax Disclosure [Abstract]	'	'
Effective tax rate (in hundredths)	31.00%	31.60%
Unrecognized tax benefits	$61,500,000	'
Unrecognized tax benefits that would affect the effective tax rate if recognized	47,200,000	'
Total interest	10,900,000	'
Total penalites	$0	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended				96 Months Ended	6 Months Ended			96 Months Ended
	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 28, 2014	Dec. 28, 2013	Jun. 28, 2014	Jun. 28, 2014	Jun. 28, 2014	Dec. 28, 2013
					Employee and director stock options [Member]	Time-based restricted stock/units [Member]	Time-based restricted stock/units [Member]	Time-based restricted stock/units [Member]	Time-based restricted stock/units [Member]	Performance-based restricted stock/units [Member]	Performance-based restricted stock/units [Member]
								2013 Stock Incentive Plan, as amended [Member]	1996 Non-Employee Director Stock Incentive Plan, as amended [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Pre-tax share-based compensation expense	$10,500,000	$11,400,000	$19,500,000	$16,700,000	'	'	'	'	'	'	'
After-tax share-based compensation expense	7,300,000	7,800,000	13,500,000	11,400,000	'	'	'	'	'	'	'
Total unrecognized compensation cost related to non-vested awards	102,000,000	'	102,000,000	'	'	'	'	'	'	'	'
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	'	'	'2 years 4 months 21 days	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of years for full vesting (in years)	'	'	'	'	'	'	'4 years	'4 years	'1 year 1 month	'3 years	'3 years
Period over which earnings per share performance is measured against specified targets (in years)	'	'	'	'	'	'	'	'	'	'3 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Outstanding at beginning of period (in shares)	'	'	'	'	1,323,000	'	'	'	'	'	'
Granted (in shares)	'	'	'	'	0	'	'	'	'	'	'
Exercised (in shares)	'	'	'	'	-440,000	'	'	'	'	'	'
Forfeited (in shares)	'	'	'	'	0	'	'	'	'	'	'
Outstanding at end of period (in shares)	'	'	'	'	883,000	'	'	'	'	'	'
Ending balance, options exercisable (in shares)	'	'	'	'	883,000	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Outstanding at beginning of period (in dollars per share)	'	'	'	'	$51.53	'	'	'	'	'	'
Granted (in dollars per share)	'	'	'	'	$0	'	'	'	'	'	'
Exercised (in dollars per share)	'	'	'	'	$48.66	'	'	'	'	'	'
Forfeited (in dollars per share)	'	'	'	'	$0	'	'	'	'	'	'
Outstanding at end of period (in dollars per share)	'	'	'	'	$52.96	'	'	'	'	'	'
Ending balance, options exercisable (in dollars per share)	'	'	'	'	$52.96	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Stock option oustanding aggregate intrinsic value as of period end	'	'	'	'	58,205,000	'	'	'	'	'	'
Stock option exercisable aggregate intrinsic value as of period end	'	'	'	'	$58,205,000	'	'	'	'	'	'
Weighted average remaining contractual life, options outstanding (in years)	'	'	'	'	'2 years 8 months 24 days	'	'	'	'	'	'
Weighted average remaining contractual life, options exercisable (in years)	'	'	'	'	'2 years 8 months 24 days	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Beginning balance outstanding (in shares)	'	'	'	'	'	926,000	'	'	'	1,078,000	'
Granted (in shares)	'	'	'	'	'	172,000	'	'	'	265,000	'
Vested (in shares)	'	'	'	'	'	-229,000	'	'	'	-259,000	'
Forfeited (in shares)	'	'	'	'	'	-19,000	'	'	'	-14,000	'
Ending balance outstanding (in shares)	'	'	'	'	'	850,000	926,000	'	'	1,070,000	1,078,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Beginning balance outstanding (in dollars per share)	'	'	'	'	'	$70.70	'	'	'	$59.85	'
Granted (in dollars per share)	'	'	'	'	'	$118.69	'	'	'	$110.97	'
Vested (in dollars per share)	'	'	'	'	'	$57.66	'	'	'	$70.03	'
Forfeited (in dollars per share)	'	'	'	'	'	$79.26	'	'	'	$84.25	'
Ending balance outstanding (in dollars per share)	'	'	'	'	'	$83.71	$70.70	'	'	$75.06	$59.85
Intrinsic value (in dollars per share)	'	'	'	'	'	$118.86	'	'	'	$118.86	'

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Supplemental Cash Flow Information [Abstract]	'	'	'	'
Interest	'	'	$9,712	$11,200
Income taxes	'	'	95,105	65,246
Unrealized gain (loss) from foreign currency hedging activities	($869)	$932	($2,021)	$856